Your SlideShare is downloading. ×
New Research Reports:silent killer  recent advances in cardiovascular disease
New Research Reports:silent killer  recent advances in cardiovascular disease
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

New Research Reports:silent killer recent advances in cardiovascular disease

131

Published on


The Silent Killer: Recent Advances in Cardiovascular Disease
There are nearly 300 medicines in clinical development to treat cardiovascular disease. This new research report examines in detail the key areas of the cardiovascular (CV) market, gathering inside opinion of cardiologists
To Read The Complete Report Kindly Visit: http://www.marketresearchreports.biz/analysis/170303
For All Latest Reports Kindly visit: http://www.marketresearchreports.biz

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
131
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. The Silent Killer: Recent Advances in Cardiovascular Disease There are nearly 300 medicines in clinical development to treat cardiovascular disease. This new research report examines in detail the key areas of the cardiovascular (CV) market, gathering inside opinion of cardiologists, to highlight the dynamic changes that are underway in this multibillion dollar marketplace. Successful players will, necessarily, need to cannibalise their existing cardiovascular franchises in order to limit the impact of generic erosion when their patents expire, whilst at the same time investing in alternative therapies with better, more efficacious outcomes. This is a significant challenge given the high barrier to entry and unmet clinical needs. Not only is cardiovascular disease a “Silent Killer”, it is also a commercial time bomb where the risk/reward ratio for any company willing to participate needs to be carefully considered. This report provides you with a systematic appraisal into the current and future CV market, including... A detailed review of the leading brands and how they are being positioned in the market, in addition to the potential impact of generics Assessment of key products in development, identifying ‘Ones to Watch’ in late-stage clinical development where proof of concept data has been established Review of products that are ‘Waiting in the Wings’ in early-stage clinical development where Point-of-Care data is being gathered Analysis of the potential of ‘Long Shots’ which represent new and innovative products where the scientific rationale has yet to be fully tested Antilipidemics The lowering of ‘bad cholesterol’ or low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) has been shown to reduce the chance of a heart attack and death in people who have an elevated risk of developing heart disease or who already have heart disease. Several drug classes are currently available to treat a range of lipid disorders; each has a different mechanism of action, safety profile and impact on blood lipid profiles to different degrees. Key drugs covered by the report include Leading brands - Lipitor (Pfizer), Crestor (AstraZeneca), Livalo (Kowa and Partners), etc... Recent generics - Atorvastatin, etc... Ones to watch - Alirocumab (Sanofi/Regeneron Pharmaceuticals), AMG 145 (Amgen), Anacetrapid (Merck & Co), etc... Waiting in the wings - RG 7652 (Roche), RN-316 (Pfizer), DRL-17822 (Dr Reddy), etc... Long shots - ALN PCS (Alnylam/The Medicine Company), etc... Just some of the key questions answered include Why are statins the gold stand in lipid lowering therapies and which is the most effective at lowering LDL-C? Will AstraZeneca’s Crestor win its fight for supremacy before generic rosuvastatin reaches the market? Why are PCSK9 inhibitors important to cardiologists and which drugs are leading the field? Kynamro approved in the US but not in Europe… what next? What new HDL-C modulating therapies are in development? What new products are in development from BMS/Simcere; Dr Reddy and DezimaPharma? N/a Market Research Report(http://www.marketresearchreports.biz/) Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. Contact: The Silent Killer: Recent Advances in Cardiovascular Disease
  • 2. M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.com Website: www.marketresearchreports.biz The Silent Killer: Recent Advances in Cardiovascular Disease

×